top of page

makes therapy processes transparent

IBEXX

"Medically comparable therapies do not always cause comparable costs. Transparent therapy costs are the prerequisite for efficient use of resources."​

With IBEXX, we are closing a knowledge gap in the introduction of new therapies. We can record, document and quantify the treatment process in routine use for each therapy. For providers and users, this makes it clear which medical, nursing, technical and administrative specialists are involved in which activities in the treatment process and to what extent. The need for personnel, material and financial resources can thus be quantified over the entire treatment process and also compared with other therapies.

Innovative therapies are often based on new treatment algorithms and therefore require different processes than conventional therapies.

When a new therapy is introduced, neither the provider nor the service provider can foresee exactly whether and how the healthcare provider's personnel and financial resource requirements will change as a result of the use of new therapies.

We therefore speak of a knowledge gap in the market launch of an innovative therapy.

knowledge b efore usage by healthcare provider u sage by healthcare provider a fter usage a s is t o be • c linical trials • customers • competitors • price (COGs) • usage of therapy • p rocess cost • p rocess quality • revenues for healthcare provider • o utcome • RWE

Through this knowledge gap

  • it is not possible to predict the actual resource requirements in routine use

  • possible resource bottlenecks or unnecessary resource consumption can only be identified very late

  • the benefits of a new therapy through resource-saving processes cannot be quantified in comparison to conventional therapies.

These factors can have a significant impact on how quickly and to what extent a new therapy is used and delivers the expected benefits to patients.

For providers and users of innovative medical therapies, it is a significant advantage if a new therapy can positively influence the processes, resource requirements and costs as well as the achievable revenue. With our software-based method IBEXX, we can identify and quantify exactly these advantages.

In order to gain market access for a drug therapy, the costs must be justified in relation to the benefits provided. This evidence is usually provided by health economic models in comparison to other therapies. 

However, a positive health economic assessment of a therapy only means basic market access. It has not yet decided whether and to what extent therapy will actually be used. We call this Therapy Access.

Factors that influence Therapy Access in real world setting are:

  • State of knowledge of the physicians about the advantages of a new therapy

  • The availability of resources (doctors, nursing) for the use of the therapy

  • Quality of the processes for using the drug (efficient use of resources)

  • whether the provided services can be charged (revenues)​

  • The maximum price that can be achieved in health economics terms for a positive cost/benefit ratio is often not the price at which the therapy is most frequently used in real use. The optimum price for maximum therapy access is usually where the ratio of (DRG) revenues and (therapy) costs is as positive as possible for the healthcare provider.

Innovative therapies can have a positive impact on resource consumption

​

Modern therapies can help to treat patients with fewer human resources.

Using the example of CAR T-cell therapy, compared to autologous stem cell therapy, it can be clearly seen that CAR T-cell treatment requires a lower number of treatment days overall (30 versus 48 treatment days).*

CAR T vs ASCT NEU

In this example, the innovative treatment requires approximately 30% less staff time than autologous stem cell transplantation due to fewer chemotherapy cycles, fewer outpatient visits and shorter hospital stays.

(adapted from Ring A, Grob B, Aerts E, Ritter K, Volbracht J, Schär B, Greiling M, Müller AMS. Resource utilization for chimeric antigen receptor T cell therapy versus autologous hematopoietic cell transplantation in patients with B cell lymphoma.Ann Hematol. 2022 Aug;101(8):1755-1767. doi: 10.1007/s00277-022-04881-0. Epub 2022 Jun 27. PMID: 35759026; PMCID: PMC9279251.); *This analysis was carried out using workflow management software

Fewer and more efficient processes relieve the burden on medical and nursing staff

Staff can be greatly relieved through the use of innovative therapies. The savings in human resources are not only beneficial in terms of hospital costs, but also in terms of the shortage of skilled workers, especially in the nursing sector.

0 5000 10000 15000 20000 25000 CAR-T ASCT time spent in minutes 269 h 16 min 389 h 47 min - 31%

Of medically equivalent therapies, preference is given to those that cause lower costs or generate higher revenues

Proof of cost reduction through more efficient processes or reduced personnel requirements is a significant competitive advantage that is not yet used for many innovative therapies.

In addition to improving the success of a therapy, healthcare providers also expect new therapies to enable to use their financial and human resources efficiently and in a predictable manner.

bottom of page